Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial Meeting Abstract
| Authors: | Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; Lu, Y. S.; Hamilton, E. P.; Zhang, Q. Y.; Tsurutani, J.; Kalinsky, K.; Xu, L.; Denduluri, N.; Rugo, H. S.; Xu, B.; Pistilli, B. |
| Abstract Title: | Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1264 |
| End Page: | S1265 |
| Language: | English |
| ACCESSION: | WOS:001087480203502 |
| DOI: | 10.1016/j.annonc.2023.10.015 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA11 -- Source: Wos |
